Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric dose-escalation study of ceritinib in ALK-altered malignancies
NL-OMON46950Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in Anaplastic Large Cell Lymphoma ALK-positive, neuroblastoma, lymphoma and 1 more, sponsored by Novartis. Primary endpoint: Dose-limiting toxicity incidence. Started Sep 2013; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positiveneuroblastomalymphomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46950.